Past News Releases
RSSDallas,TX (PRWEB) December 27, 2014
Increase in public awareness about cystic fibrosis is one of the main factors which have contributed to the growth of the global cystic fibrosis market. Cystic fibrosis is a chronic condition in which the lungs and the digestive system become clogged with mucus. The condition is more common among the Caucasian population than people of African or Asian descent. The global cystic fibrosis market is expected to grow at a compound annual growth rate of 32.50 percent during the period from 2015 to 2019.
In recent years, CFTR modulator drugs are becoming more popular for treating cystic fibrosis as these drugs target the cause of the disease. High degree of unmet needs for drugs is one of the major drivers in the global cystic fibrosis market. One of the major challenges to the growth of the market is the high cost of treatment. Medication and hospitalization costs are quite high for this condition. Cayston, Kalydeco, Colomycin, Zenpep, Pulmozyme and TOBI Podhaler are some of the drugs that are used for treating cystic fibrosis.
Key players in the global cystic fibrosis market are Actavis, Novartis, Gilead Sciences, Vertex Pharmaceuticals and F. Hoffmann-La Roche. Other prominent players in the market include Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics, Boehringer Ingelheim, Chiesi Farmaceutici, Insmed, Pharmaxis, PharmaSwiss, Genzyme, Johnson & Johnson, Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, Proteostasis Therapeutics, PTC Therapeutics, United Medical and Venus Remedies. The global market for cystic fibrosis can be segmented on the basis of molecule type, route of administration, dosage form and geographical regions. On the basis of molecule type, the market can be segmented into biologics and small molecules. According to route of administration, the market can be segmented into oral, parenteral and topical. On the basis of dosage form, the market can be categorized into solid and liquid. Key leading countries in the global cystic fibrosis market are the US, the UK, France, Canada and Italy.
Order a copy of this report at (Prices start at US $3000 for a single user PDF) http://www.reportsnreports.com/Purchase.aspx?name=320610.
Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
06. Introduction
07. Disease Overview
08. Market Landscape
09. Market Segmentation by Molecule Type
10. Market Segmentation by Route of Administration
11. Market Segmentation by Dosage Form
12. Geographical Segmentation
13. Key Leading Countries
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
22. Key Vendor Analysis
23. Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot Of Cystic Fibrosis Disease
Exhibit 3: Defects Caused by CFTR Mutation
Exhibit 4: Epidemiology of Cystic Fibrosis in the World 2012
Exhibit 5: Prevalence of Cystic Fibrosis by Country 2014
Exhibit 6: Prevalence Number of Cystic Fibrosis by Country 2014
Exhibit 7: Snapshot of US Prevalence of Cystic Fibrosis 2014
Exhibit 8: Forecast of Cystic Fibrosis Prevalence in US 2014-2019
Exhibit 9: Epidemiology Based on the Education Level in US, 2011
Exhibit 10: Epidemiology based on the Marital Status in US, 2011
Other Reports on Pharmaceuticals –
Global Huntington's Disease Therapeutics Market 2014-2018
One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects.
Key players in the Global Huntington's Disease Therapeutics Market: H. Lundbeck A/S and Valeant Pharmaceuticals International Inc. Other Prominent Vendors in the market are: Auspex Pharmaceuticals, GlaxoSmithKline, Ipsen, Omeros, Palobiofarma, Pfizer, Prana Biotechnology, Raptor Pharmaceutical, Siena Biotech, SOM Biotech and Teva Pharmaceutical Industries.
Global Lysosomal Storage Diseases Market 2014-2018
One of the prominent trends in this market is an increase in awareness among regulatory authorities. Regulatory bodies are steadily working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area.
Key players in the Global Lysosomal Storage Diseases market: Actelion Pharmaceuticals Ltd., BioMarin Pharmaceutical Inc., Genzyme Corp. and Shire plc. Other Prominent Vendors in the market are: Mylan, Pfizer, Protalix, Raptor, Recordati, and Sigma-Tau.
Browse other new reports on Infiniti Research Limited.
About US
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5,000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email the details to sales(at)reportsandreports(dot)com.